Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTime Finance Regulatory News (TIME)

Share Price Information for Time Finance (TIME)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.75 (1.66%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £42.17m
TIME Live PriceLast checked at - London Stock Exchange

Intraday Time Finance Share Chart

Full Year Trading Update

29 Jun 2023 07:00

RNS Number : 2982E
Time Finance PLC
29 June 2023
 

29 June 2023

Time Finance plc

("Time Finance", the "Group" or the "Company")

 

Full Year Trading Update

 

Strong trading momentum maintained

 Significant increase in Profits and Earnings Per Share; Record Lending Book of c£169m at year-end

 

Time Finance plc, the AIM listed independent specialist finance provider is pleased to issue the following trading update for the twelve months ended 31 May 2023. The results reflect the success of the Company's continued focus on own-book lending to UK businesses, with the Lending Book reaching an all-time high of c£169m as at 31 May 2023. Significant increases have also been achieved in revenue, profit and across other key performance indicators.

 

Unaudited financial highlights:

 

· Own-Book lending origination up 14% to £73.4m (FY 2021/22: £64.4m)

· Revenue increased 16% to £27.4m (FY 2021/22: £23.6m)

· 273% increase in Profit Before Tax ("PBT") to £4.1m (FY 2021/22: £1.1m)

· 250% increase in Earnings Per Share up to 3.5 pence per share (FY 2021/22: 1.0pps)

· Strong visibility of future earnings with unearned income up 24% to £20.7m as at 31 May 2023 (31 May 2022: £16.7m)

· Gross lending-book up 23% to £168.9m as at 31 May 2023 (31 May 2022: £136.8m)

· Net Arrears reduced to 6% of the gross lending book as at 31 May 2023 (31 May 2022: 7%)

· A prudent increase in the Credit Risk Provision to £4.2m as at 31 May 2023 (31 May 2022: £3.6m)

· Net Tangible Assets up 11% to £33.9m as at 31 May 2023 (31 May 2022: £30.5m)

· Supportive, long-term funding partners with unused lending headroom of approximately £50m at year-end

 

The significant increase in revenue has been driven primarily by growth in the Invoice Finance division and the 'Hard Asset' subset of the Asset division. Both of these growth areas operate in the larger-ticket, more secured lending space. The performance highlights the effectiveness of the strategic focus on increasing the Group's average deal size and, where appropriate, taking greater security on lending.

 

The Group will publish its audited Annual Report and Financial Statements on 26 September 2023.

 

Ed Rimmer, Chief Executive Officer commented:

"I am delighted to report these full-year results which demonstrate the successful implementation of the Group's Medium-Term Strategy. Two years in, we remain on track to achieve our four-year plan's stated targets.

 

I am also very pleased to confirm that the significant growth achieved during the year has been made whilst continuing to generate appropriate margins, control credit and spread risk. To have delivered such growth, despite much publicised, wide-ranging and challenging macroeconomic factors, is testament to the hard work of our team, the investments we have made over the last few years which are starting to have a very positive impact, and to the continued robust nature of demand for finance from UK businesses.

 

We have built strong foundations for continued growth. The Board is committed to further increasing shareholder value through the delivery of its stated strategy and continues to look forward with cautious optimism."

 

 

For further information, please contact:

 

Time Finance plc

Ed Rimmer, Chief Executive Officer 01225 474230

James Roberts, Chief Financial Officer 01225 474230

 

Cenkos (NOMAD)

Ben Jeynes / Max Gould (Corporate Finance) 0207 3978900

Michael Johnson / George Budd (Sales)

 

Walbrook PR 0207 9338780

Paul Vann /Joe Walker 07768 807631

paul.vann@walbrookpr.com

 

About Time Finance:

 

Time Finance's purpose is to help UK businesses thrive and survive through the provision of flexible funding facilities. It offers a multi-product range for SMEs concentrating on asset, loan and invoice finance. While focussed on being an 'own-book' lender, the Group does retain the ability to broke-on deals where appropriate, enabling it to optimize business levels through market and economic cycles.

 

More information is available on the Company website www.timefinance.com.

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFPMRTMTJTBAJ
Date   Source Headline
21st Sep 20217:00 amRNS2021 Final Results
7th Sep 20217:00 amRNSNotice of Final Results and Investor Presentation
16th Jun 20217:00 amRNSYear-end Trading Update
10th Jun 20217:00 amRNSPermanent CEO Appointment & Investor Presentation
4th Jun 202111:30 amRNSHolding(s) in Company
4th Jun 202111:25 amRNSHolding(s) in Company
27th May 20215:29 pmRNSEmployee Benefit Trust Share Purchase
27th May 20217:00 amRNSExercise of Options
21st May 20217:00 amRNSUnapproved Share Option Scheme – Vesting of Awards
6th May 20217:00 amRNSNew Loan Accreditation & Financial Calendar Update
22nd Apr 20217:00 amRNSCorporate Update
9th Apr 20212:58 pmRNSEmployee Benefit Trust Share Purchase
26th Mar 20217:00 amRNSDirectorate Change
3rd Mar 20217:00 amRNSFurther re Directorate Change
19th Feb 202112:04 pmRNSDirectorate Changes
3rd Feb 20217:00 amRNSTechnology Infrastructure Update
19th Jan 20217:00 amRNSInterim Results
12th Jan 20217:00 amRNSHolding in Company
12th Jan 20217:00 amRNSHolding in Company
6th Jan 20217:00 amRNSDirectorate Changes
15th Dec 20205:15 pmRNSTR-1: Holding in Company - CORRECTION
9th Dec 20207:00 amRNSHalf Year Trading Update & Investor Presentation
1st Jun 20103:19 pmRNSResult of EGM
28th May 20107:00 amRNSUpdate
6th May 20108:37 amRNSStrategic Review - update
6th May 20107:01 amRNSNotice of EGM
6th May 20107:00 amRNSAppointment of adviser
4th May 201011:22 amRNSForm 8.3 - Timestrip PLC
4th May 20107:00 amRNSForm 8 (OPD) Timestrip
19th Apr 20107:30 amRNSStrategic Review Update and Suspension
19th Apr 20107:30 amRNSSuspension - Timestrip plc
24th Mar 20109:50 amRNSRule 8.1- (Timestrip)
19th Mar 201012:47 pmRNSStrategic Review - Update
18th Mar 20107:00 amRNSStrategic Review
5th Feb 20109:04 amRNSDirectorate Change
3rd Feb 20104:29 pmRNSAIM Rule 17
1st Feb 20107:00 amRNSContract Win - Toothbrush Order
5th Nov 200912:23 pmRNSUK Packaging Awards
28th Oct 20097:00 amRNSTimestrip IV - First full adoption by NHS Trust
26th Oct 20097:00 amRNSTimestrip Medical - 1st order in North America
14th Sep 20097:01 amRNSHalf Yearly Report
14th Sep 20097:00 amRNSNHS trials and appointment of distributor
24th Jul 20092:18 pmRNSResult of AGM
6th Jul 20097:00 amRNSNew distribution agreement
1st Jul 20097:00 amRNSPreliminary findings on Timestrip IV
29th Jun 20091:26 pmRNSNotice of AGM
11th Jun 20097:00 amRNSFinal Results
8th May 20097:00 amRNSIssue of Equity
5th May 20097:00 amRNSLuton & Dunstable Hospital orders TimestripIV
28th Apr 20097:00 amRNSTimestripIV showcased in NHS funded project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.